Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Financial Officer

Chief Executive Officer

President and COO

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technol...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-17	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-04-17	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-04-16	Premium	sold	Premium	Premium	Premium	-
2024-04-16	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-04-16	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-04-04	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2024-04-04	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2024-04-04	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2024-04-03	Premium	gifted	Premium	Premium	Premium	Chief Executive Officer
2024-04-03	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2024-04-03	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2024-04-03	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2024-04-02	Premium	sold	Premium	Premium	Premium	-
2024-04-01	Premium	acquired	Premium	Premium	Premium	-
2024-04-01	Premium	acquired	Premium	Premium	Premium	-
2024-04-01	Premium	acquired	Premium	Premium	Premium	-
2024-04-01	Premium	acquired	Premium	Premium	Premium	-
2024-03-28	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2024-03-28	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2024-03-28	Premium	gifted	Premium	Premium	Premium	Chief Executive Officer
2024-03-28	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2024-03-21	Premium	acquired	Premium	Premium	Premium	President and COO
2024-03-21	Premium	sold	Premium	Premium	Premium	President and COO
2024-03-19	Premium	sold	Premium	Premium	Premium	-
2024-03-13	Premium	sold	Premium	Premium	Premium	Chief Financial Officer

RXRX - Recursion Pharmaceuticals, Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for RXRX